Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Fever × dabrafenib × Clear all

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 26 Neoplasms 15 Neoplasm Metastasis 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Glioma 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thyroid Cancer, Papillary 1 Skin Neoplasms 1 Oligodendroglioma 1 Nonseminomatous germ cell tumor 1 Neurocytoma 1 Multiple Myeloma 1 Leukemia, Hairy Cell 1 Hematologic Neoplasms 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Ganglioneuroma 1 Ganglioglioma 1 Fever 1 Biliary Tract Neoplasms 1 Astrocytoma 1 Ameloblastoma 1 Adamantinoma 1

Interventions

pegfilgrastim 3 Vancomycin 2 Filgrastim 2 trametinib 1 ofatumumab 1 liposomal amphotericin B 1 dabrafenib 1 Teicoplanin 1 Tazobactam 1 Surveys and Questionnaires 1 Ritonavir 1 Quality of Life 1 Povidone-Iodine 1 Piperacillin, Tazobactam Drug Combination 1 Piperacillin 1 Metformin 1 Lenalidomide 1 Itraconazole 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Granulocyte Colony-Stimulating Factor 1 Doxorubicin 1 Docetaxel 1 Cyclophosphamide 1 Cloxacillin 1 Ceftazidime 1 Cefepime 1 Caspofungin 1 Bevacizumab 1 Amikacin 1 Administration, Intravesical 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03551626 2025-04-29

COMBI-APlus

Novartis

Phase 3 Completed

552 enrolled 12 charts

Fever, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡